UK-CAB 16 – HIV related brain impairment – SMART study – Tibotec

24 February 2006

Program for the meeting
Reading materials

Post meeting documents

SMART PowerPoint Slides [121 Kb]

Programme

09:00 – 09:30 Registration and coffee
09:30 – 10:30 CAB Future meetings – Robert James / Mark McPherson
10:30 – 11:00 Break
11:00 – 12:30 HIV Related Brain Impairment – Heather George, Brighton
12:30 – 13:30 Lunch
13:30 – 15:00 Company meeting: Tibotec
15:00 – 15:30 Break
15:30 – 15:45 National Treatment Support Project – Elijah Amooti
15:45 – 16:15 SMART Study – Simon Collins
16:15 – 17:00 Feedback from Meetings and Conferences / Future Meetings

Link to top of page

Reading materials

Tibotec

The two links to Tibotec articles written by Mark Mascolini for NATAP, were both in the Jan/Feb issue of HTB.

HTB Volume 7 Number 1/2 Page 11 – The TMC125: some good and bad news:
The issue is related to potency, since the stopping of one recent trial.
HTB Volume 7 Number 1/2 Page 20 – Understanding TMC114 power against resistant HIV
The discussion is about potency, with or without T-20, TMC-114 is now on expanded access in the UK.

HIV dementia

http://www.emedicine.com/neuro/topic447.htm

This site offers a background into neurological complications from HIV, provides simple information about how it occurs, the frequency, diagnosis and treatment. There are also a range of links to other related topics.

Update on the Neurological Manifestations of HIV

Justin McArthur, MBBS, MPH

PRN Notebook, www.prn.org

http://www.prn.org/prn_nb_cntnt/vol10/num3/mcarthur_frm.htm

or

PDF File [192 Kb]

AIDS Dementia Complex

Dementia is a brain disorder that affects a person’s ability to think clearly and can impact his or her daily activities. AIDS dementia complex (ADC)-dementia caused by HIV infection-is a complicated syndrome made up of different nervous system and mental symptoms. These symptoms are somewhat common in people with HIV disease.

Project Inform factsheet, April 2002

http://www.projinf.org/fs/dementia.html

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.

Link to top of page

Edit
Published: February 24, 2006
Last edited: August 14, 2013